TROW
51
3
NWL
50
6
LB
41
7
NTAP
66
2
DHI
44
-4
PBI
65
5
OMC
61
6
AVGO
22
2
ROP
59
5
BWA
46
2
STT
64
4
F
47
4
IPG
53
4
HST
58
18
KMI
69
2
IBM
60
6
URBN
42
4
SIG
49
6
DE
56
10
ABT
62
5
TROW
51
3
NWL
50
6
LB
41
7
NTAP
66
2
DHI
44
-4
PBI
65
5
OMC
61
6
AVGO
22
2
ROP
59
5
BWA
46
2
STT
64
4
F
47
4
IPG
53
4
HST
58
18
KMI
69
2
IBM
60
6
URBN
42
4
SIG
49
6
DE
56
10
ABT
62
5
Financhill
Back

Materialise NV 10K Form

Buy
67

MTLS
Materialise NV

Last Price:
7.37
Seasonality Move:
7.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MTLS News And Ratings

See the #1 stock for the next 7 days that we like better than MTLS

MTLS Financial Statistics

Sales & Book Value

Annual Sales: $277.29M
Cash Flow: $-341.5K
Price / Cash Flow: 92.57
Annual Sales: $4.67
Price / Book: 1.6

Profitability

EPS (TTM): 0.18480
Net Income (TTM): $11.15M
Gross Margin: $157.12M
Return on Equity: 4.27%
Return on Assets: 2.6%

Materialise NV Earnings Forecast

Key Materialise NV Financial Ratios

  • The Gross Profit Margin over the past 12 years for MTLS is 56.66%.
  • The Selling, General & Administrative Expenses for MTLS have been equal to 35.23% of Gross Profit Margin.
  • The Research & Development expenses have been 14.87% of Revenue.
  • The Interest Expense is 26.05% of Operating Income.
  • The Net Earning history of MTLS is 2.62% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Materialise NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Software
Sector: Information Technology
Current Symbol: MTLS
CUSIP: 57667T
Website: materialise.com

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 1.81
Quick Ratio: 1.54

Price-to-Earnings

Trailing P/E Ratio: 62.81
Forward P/E Ratio: 25.92

MTLS Technical Analysis vs Fundamental Analysis

Buy
67
Materialise NV (MTLS) is a Buy

Is Materialise NV a Buy or a Sell?

  • Materialise NV stock is rated a Buy
    The current Materialise NV [MTLS] share price is $7.48. The Score for MTLS is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.